The U.S. stock market delivers a hefty long-term average return of 11% per annum.

Peter Prince

2017-03-09 05:32:00 Thu ET

From 1927 to 2017, the U.S. stock market has delivered a hefty average return of about 11% per annum. The U.S. average stock market return is high in stark contrast to the average returns on bonds, currencies, mutual funds, exchange funds, warrants, and commodities such as gold, silver, oil, and wheat. 

Behavioral economists such as Nobel Laureate Richard Thaler have coined this macrofinancial anomaly *the equity premium puzzle*.

This equity premium puzzle suggests that the U.S. double-digit performance is too high to reasonably reflect the typical investor's relative risk aversion in light of low consumption growth.

While many scholars strive to resolve this equity premium puzzle with complex math models, some recent evidence suggests that the American stock market experience proves to be the exception that defies the rule of thumb.

In other words, the American stock market stands out of the international crowd in terms of long-term average aggregate performance.

Positive U.S. investor sentiment highlights the long-term outperformance of the U.S. stock market relative to many other asset classes.

U.S. stocks remain the primary investment vehicle for most global institutional investors and North American retail investors.

Information technology usage, diffusion, and proliferation have spurred the U.S. spectacular stock market vibrancy over the past few decades.


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

America and China play the game of chicken over trade and technology.

John Fourier

2018-05-01 11:38:00 Tuesday ET

America and China play the game of chicken over trade and technology.

America and China play the game of chicken over trade and technology, whereas, most market observers and economic media commentators hope the Trump team to

+See More

Amy Chua and Jed Rubenfeld suggest that relatively successful ethnic groups exhibit common cultural traits in America.

Laura Hermes

2023-05-21 12:26:00 Sunday ET

Amy Chua and Jed Rubenfeld suggest that relatively successful ethnic groups exhibit common cultural traits in America.

Amy Chua and Jed Rubenfeld suggest that relatively successful ethnic groups exhibit common cultural traits in America. Amy Chua and Jed Rubenfeld (2015)

+See More

Zuckerberg announces his major changes in Facebook's newsfeed algorithm and user authentication.

Becky Berkman

2018-01-07 09:33:00 Sunday ET

Zuckerberg announces his major changes in Facebook's newsfeed algorithm and user authentication.

Zuckerberg announces his major changes in Facebook's newsfeed algorithm and user authentication. Facebook now has to change the newsfeed filter to prior

+See More

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential user growth.

Fiona Sydney

2020-05-28 15:37:00 Thursday ET

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential user growth.

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential business growth. Laure Reillier and Benoit

+See More

Sino-American trade talks make positive progress over 3 consecutive days.

Joseph Corr

2019-01-17 10:41:00 Thursday ET

Sino-American trade talks make positive progress over 3 consecutive days.

Sino-American trade talks make positive progress over 3 consecutive days as S&P 500 and global stock market indices post 3-day win streaks. Asian and Eu

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More